The silent treatment: siRNAs as small molecule drugs

5 January 2006

journal article
review article
Published by Springer Nature in Gene Therapy

Vol. 13 (6) , 541-552
https://doi.org/10.1038/sj.gt.3302703

Abstract

As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active – a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.

Keywords

This publication has 123 references indexed in Scilit:

A Genetic Screen for Candidate Tumor Suppressors Identifies REST
Cell, 2005
Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein
Nature, 2005
Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets
Cell, 2005
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
Nature Biotechnology, 2004
The functions of animal microRNAs
Nature, 2004
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Nature Medicine, 2004
A resource for large-scale RNA-interference-based screens in mammals
Nature, 2004
RNA Interference in Mammalian Cells by Chemically-Modified RNA
Biochemistry, 2003
Induction of an interferon response by RNAi vectors in mammalian cells
Nature Genetics, 2003
Expression profiling reveals off-target gene regulation by RNAi
Nature Biotechnology, 2003